Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-HTP and Creatine for Hypoxia-Related Depression
NCT02922725Phase 4Terminated
- Start
- Nov 2016
- Primary completion
- May 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of 5-hydroxytryptophan and creatine in major depressive disorder (MDD) (3 arms). Primary endpoint: Hamilton Depression Rating Scale at 8 weeks. Started Nov 2016; status: terminated.
02
Drugs
5-hydroxytryptophancreatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02922725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02922725.